Acetylcysteine Against Acute Renal Insult During Cardiopulmonary Bypass.

• Status: Suspended
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether N-acetylcysteine is effective in the prophylaxis of post-cardiopulmonary bypass acute renal impairment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Far Eastern Memorial Hospital
• Collaborator: Synmosa Biopharma Corp.
• Treatments: Acetylcysteine; N-monoacetylcystine

Criteria

Inclusion Criteria:

• All patients who will received cardiac surgery with cardiopulmonary bypass

Exclusion Criteria:

1. Dialyzed patients

2. Acute renal failure

3. Advanced left ventricular systolic dysfunction defined as left ventricular ejection fraction ≦ 35%.

4. Acute chronic obstructive lung disease or asthma exacerbation

5. Allergy to N-acetylcysteine